Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors in Phase III NSCLC Trial
Genentech Divarasib Phase III Trial has delivered encouraging results after the company announced positive findings from its Phase III Krascendo 1 study. The landmark head-to-head clinical trial compared the investigational therapy divarasib with the approved first-generation KRAS G12C inhibitors, sotorasib and adagrasib, in patients with previously treated advanced non-small cell lung cancer....
English
Arabic
Français
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian